Please assess the completion status of the following clinical trial:

Trial Title: S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV breast cancer~  * Metastasis to the ipsilateral supraclavicular lymph nodes allowed~* HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting~* No effusions or ascites as only sites of disease~* No primary or metastatic brain or central nervous system tumor~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin normal~* aspartate aminotransferase or Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2.5 times ULN~Renal:~* Not specified~Cardiovascular:~* left ventricular ejection fraction normal by multigated radionuclide angiography or echocardiogram (patients who have received prior anthracycline therapy)~* No clinical evidence or history of cardiomyopathy~Other:~* No pre-existing grade 2 or greater motor or sensory peripheral neuropathy except abnormalities due to cancer~* No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer currently in complete remission~* No known sensitivity to E. coli-derived proteins~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* At least 6 months since prior chemotherapy~* Prior anthracycline as adjuvant therapy allowed~* No prior cumulative dose of doxorubicin more than 360 mg/m\^2~* No prior cumulative dose of epirubicin more than 720 mg/m\^2~* No more than 1 prior adjuvant or neoadjuvant chemotherapy regimen for primary disease~* No prior docetaxel~* No prior vinorelbine~* Prior paclitaxel allowed~Endocrine therapy:~* Prior hormonal therapy as adjuvant therapy or for metastatic breast cancer allowed~* No concurrent hormonal therapy~Radiotherapy:~* At least 3 weeks since prior radiotherapy~Surgery:~* At least 2 weeks since prior surgery and recovered

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab, docetaxel, vinorelbine and filgrastim (Type: EXPERIMENTAL): Trastuzumab, docetaxel, vinorelbine and filgrastim

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete